Entry criteria HbA1c (%) | HbA1c baseline | BMI baseline | Age baseline | Weight baseline | eGFR baseline | Per cent HbA1c <7% PBO | Per cent HbA1c <7% drug | Weight loss PBO | Weight loss drug | Reduction HA1c PBO | Reduction HbA1c drug | Difference HbA1c | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dapagliflozin | |||||||||||||
Bailey et al14 | 7–10 | 7.9–8.2 | 31.5 | 52.7–53.7 | NR | NR | 26 | 41 | 0.9 | 2.9 | 0.3 | 0.84 | 0.54 |
Bolinder et al11 | 6.5–8.5 | 7.2 | 31.0 | 60.6–60.8 | 90.9–92.1 | ≥30 to ≥90 | NR | NR | 0.9 | 3.0 | 0.1 | 0.39 | 0.29 |
Henry et al12 | 7.5–12 | 9.1 | NR | 51.0–52.7 | 87.2–88.4 | NR | 35 | 47 | 1.4 | 3.3 | 1.44 | 1.98 | 0.54 |
Canagliflozin | |||||||||||||
Lavalle-Gonzalez et al19 | 7.0–10.5 | 7.9 | 31.8 | 55.4 | 87.2 | 87.7 to 90.2 | 29 | 46; 58 | 1–2 | 3.3, 3.7 | 0.17 | 0.79, 0.94 | 0.62, 0.77 |
Empagliflozin | |||||||||||||
Haring et al16 2014 | 7–10 | 7.9 | 29.2 | 55.7 | 81.2 | 89.0 | 23 | 38; 39 | 0.45 | 2.0. 2.5 | 0.13 | 0.70, 0.77 | 0.57, 0.64 |
Ipragliflozin | |||||||||||||
Kashiwagi et al24 | 7.4–9.9 | 8.25–8.38 | 25.47–25.96 | 56.2–57.7 | NR | NR | 0 | 21.4 | −0.63 | −2.33 | 0.38 | −0.87 | −1.30 |
HbA1c in per cent; age in years; BMI in kg/m2; weight in kg; eGFR in mL/min/1.73 m2.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; NR, not reported; PBO, placebo.